|
|
Response Genetics, Inc. is engaged in the research and development of pharmacogenomic cancer diagnostic tests based on its proprietary and patented technologies
which enable extraction and analysis of genetic information from genes derived from tumor samples stored as formalin-fixed and paraffin embedded specimens. RGI currently generates revenue primarily from the sales of its proprietary analytical pharmacogenomic testing services of clinical trial specimens to the pharmaceutical industry.
( Total: 3 Current Stock Recommendations )
|
|
|
|
|
|
|
|
|
|
* As of 5/24/2013 12:00 AM
|
|
|
|
|